These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
3. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689 [TBL] [Abstract][Full Text] [Related]
4. Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. Ternant D; Hénin E; Cartron G; Tod M; Paintaud G; Girard P Br J Clin Pharmacol; 2009 Oct; 68(4):561-73. PubMed ID: 19843059 [TBL] [Abstract][Full Text] [Related]
5. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Marcus R; Hagenbeek A Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982 [TBL] [Abstract][Full Text] [Related]
7. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). Martin P; Jung SH; Pitcher B; Bartlett NL; Blum KA; Shea T; Hsi ED; Ruan J; Smith SE; Leonard JP; Cheson BD Ann Oncol; 2017 Nov; 28(11):2806-2812. PubMed ID: 28945884 [TBL] [Abstract][Full Text] [Related]
8. Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma. Ternant D; Cartron G; Hénin E; Tod M; Girard P; Paintaud G Br J Clin Pharmacol; 2012 Apr; 73(4):597-605. PubMed ID: 21999172 [TBL] [Abstract][Full Text] [Related]
9. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study. Mondello P; Steiner N; Willenbacher W; Wasle I; Zaja F; Zambello R; Visentin A; Mauro E; Ferrero S; Ghione P; Pitini V; Cuzzocrea S; Mian M Ann Hematol; 2016 Jun; 95(7):1107-14. PubMed ID: 27103007 [TBL] [Abstract][Full Text] [Related]
10. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence. Morschhauser F; Dreyling M; Rohatiner A; Hagemeister F; Bischof Delaloye A Oncologist; 2009; 14 Suppl 2():17-29. PubMed ID: 19819921 [TBL] [Abstract][Full Text] [Related]
11. Rituxan immunotherapy and zevalin radioimmunotherapy in the treatment of non-Hodgkin's lymphoma. White CA Curr Pharm Biotechnol; 2003 Aug; 4(4):221-38. PubMed ID: 14529425 [TBL] [Abstract][Full Text] [Related]
12. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. Press OW; Unger JM; Rimsza LM; Friedberg JW; LeBlanc M; Czuczman MS; Kaminski M; Braziel RM; Spier C; Gopal AK; Maloney DG; Cheson BD; Dakhil SR; Miller TP; Fisher RI J Clin Oncol; 2013 Jan; 31(3):314-20. PubMed ID: 23233710 [TBL] [Abstract][Full Text] [Related]
13. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Keating GM Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951 [TBL] [Abstract][Full Text] [Related]
14. The optimal management of follicular lymphoma: an evolving field. Ujjani C; Cheson BD Drugs; 2013 Sep; 73(13):1395-403. PubMed ID: 23884816 [TBL] [Abstract][Full Text] [Related]
15. Towards a chemotherapy-free approach in indolent lymphoma. Buske C Lancet Oncol; 2014 Nov; 15(12):1281-2. PubMed ID: 25439681 [No Abstract] [Full Text] [Related]
16. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma. Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285 [TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab. Czuczman MS; Grillo-López AJ; Alkuzweny B; Weaver R; Larocca A; McLaughlin P Leuk Lymphoma; 2006 Sep; 47(9):1830-40. PubMed ID: 17064996 [TBL] [Abstract][Full Text] [Related]
18. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas. Feugier P Future Oncol; 2015; 11(9):1327-42. PubMed ID: 25952779 [TBL] [Abstract][Full Text] [Related]